Zokinvy ((lonafarnib) achieves FDA approval
Zokinvy ((lonafarnib) achieves FDA approval
… Eiger BioPharmaceuticals Earns FDA Approval For Zokinvy …

The first treatment for Hutchinson-Gilford Progeria Syndrome and some progeroid laminopathies

John G. Baresky

The U.S. Food and Drug Administration (FDA) has issued approval to Eiger BioPharmaceuticals (NASDAQ: EIGR) for Zokinvy (lonafarnib) based on an indication to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in patients one year of age and older. Zokinvy was given a Priority Review to quicken the pace of its evaluation by the FDA and speed its availability to patients and healthcare professionals.

Patients with Hutchinson-Gilford progeria syndrome and progeroid laminopathies typically have accelerated cardiovascular disease from the buildup of defective progerin or progerin-like protein in cells. …

About

Bare Sky Marketing — Healthcare Content Writing

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store